Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: TRI

Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout


STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobitm) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the phase 2 COMPARE study comparing the efficacy of SEL-212, a combination of Selecta's tolerogenic ImmTORtm immune tolerance platform and a therapeutic uricase enzyme (pegadricase), to pegloticase (KRYSTEXXA®), the currently approved uricase in the US, for the treatment of chronic refractory gout.

Per FDA guidance on Statistical Considerations for Clinical Trials during the COVID-19 Public Health Emergency, the statistical analysis plan was modified and submitted to FDA prior to database lock to address the potential impact of the COVID-19 pandemic on the statistical analysis of the study endpoints. This was necessary due to increased protocol deviations in the intention-to-treat (ITT) population observed during the ongoing COVID-19 pandemic. Data are therefore presented per protocol (PP*) and ITT.

Topline results from the phase 2 COMPARE study are as follows:

"There is a clear need for a next-generation treatment for chronic refractory gout, and the phase 2 COMPARE study demonstrated that SEL-212 led to a statistically significant reduction of serum uric acid levels versus standard of care in patients suffering from this painful, debilitating disease," said Robert T. Keenan, MD, MBA, MPH, board certified rheumatologist at Duke University School of Medicine and Principal Investigator of the COMPARE study. "I believe that SEL-212 could meaningfully impact the lives of patients and provide a much-needed alternative in the treatment paradigm for patients with chronic refractory gout."

"We believe SEL-212, if approved, could improve the lives of patients with chronic refractory gout, as data suggest that SEL-212 addresses several key unmet needs, including the potential to provide a persistent and significant reduction in SUA levels with a convenient monthly treatment," said Carsten Brunn, Ph.D., President and CEO of Selecta. "The topline data from our COMPARE study demonstrate the promise of our ImmTOR platform to allow sustained therapeutic activity when combined with a highly immunogenic enzymatic therapy, such as our proprietary pegadricase. We look forward to evaluating SEL-212 in partnership with Sobi in our ongoing double blinded, placebo-controlled phase 3 DISSOLVE programme and continuing to advance our ImmTOR platform in gene therapy."

Guido Oelkers, Ph.D., President and CEO of Sobi, added, "SEL-212 is a highly differentiated product candidate for the treatment of chronic refractory gout, and these data reinforce our excitement about its potential. We are proud to collaborate with Selecta for the ongoing phase 3 programme which has already enrolled the first patient."

SEL-212 has been licensed to Sobi, with Sobi undertaking development, regulatory and commercial activities in all markets outside of China. Sobi and Selecta recently announced the initiation of two double-blinded, placebo-controlled phase 3 clinical studies (DISSOLVE I and DISSOLVE II) of SEL-212 for the treatment of chronic refractory gout. Topline data from the DISSOLVE programme is expected in the second half of 2022, and a Biologics License Application (BLA) filing is expected in the first quarter of 2023.

About the phase 2 COMPARE study
The phase 2 COMPARE study evaluated 170 patients with chronic refractory gout, with 83 receiving an infusion of SEL-212 once monthly for six months and 87 receiving an infusion of pegloticase twice monthly for six months. The primary endpoint measure was a comparison of the percentage of patients on SEL-212 versus pegloticase who achieved and maintained a reduction of serum uric acid (SUA) < 6 mg/dL for at least 80% of the time during months three and six combined. Key secondary endpoint measures included a comparison of the percentage of patients on SEL-212 versus pegloticase who achieved and maintained a reduction of serum uric acid (SUA) < 6 mg/dL for at least 80% of the time during month 3 and during month 6, separately, and reduction of mean SUA assessed at the three- and six-month time points.

*The PP population is defined as patients who were administered any amount of study medication and have completed at least 65% of the study dosing visits unless early termination from the study occurred after study drug withdrawal due to meeting stopping rules or due to an adverse event, or due to investigator discretion and who have no major protocol deviations affecting the primary efficacy assessments.

About SEL-212
SEL-212 is a novel combination product candidate designed to sustain control of serum uric acid (SUA) levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. SEL-212 consists of pegadricase, Selecta's proprietary pegylated uricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies (ADAs). ADAs develop due to unwanted immune responses to biologic medicines, rendering these therapies less potent, which remains an issue across multiple therapeutic modalities and disease states including chronic refractory gout.

About Chronic Refractory Gout
Gout is the most common form of inflammatory arthritis with more than 8.3 million patients in the United States having been diagnosed with gout, which is caused by high levels of uric acid in the body that accumulate around the joints and other tissues, and can result in flares that cause intense pain. Approximately 160,000 patients in the United States suffer from chronic refractory gout, a painful and debilitating condition in which patients are not able to get their SUA levels below 6 mg/dL and therefore have several flares per year and can develop nodular masses of uric acid crystals known as tophi. Elevated SUA levels have been associated with diseases of the heart, vascular system, metabolism, kidney and joints.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTORtm platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical program in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.  

About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Corporate Communication and Investor Relations, at 22:15 CEST on 30 September 2020.

For more information please contact:

SobiPaula Treutiger, Head of Communication & Investor Relations
+46 733 666 599
paula.treutiger@sobi.com  

Linda Holmström, Corporate Communications & Investor Relations
+46 708 734 095
linda.holmstrom@sobi.com 

Selecta

For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com

For Media:

Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-and-selecta-biosciences-announce-topline-data-of-sel-212-from-the-phase-2-compare-study-support,c3208102

The following files are available for download:

https://mb.cision.com/Main/14266/3208102/1313297.pdf

Press release - phase 2 data SEL-212

SOURCE Swedish Orphan Biovitrum AB


These press releases may also interest you

23 oct 2020
Technavio has been monitoring the smart mattress market and it is poised to grow by USD 819.27 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period. The report offers an up-to-date analysis regarding the current...

23 oct 2020
The liquid biopsy market is poised to grow by USD 4.02 billion during 2020-2024, progressing at a CAGR of almost 38% during the forecast period. The report on the liquid biopsy market provides a holistic update, market size and forecast, trends,...

23 oct 2020
The dPCR market is poised to grow by USD 518.69 million during 2020-2024, progressing at a CAGR of over 24% during the forecast period. The report on the dPCR market provides a holistic update, market size and forecast, trends, growth drivers, and...

23 oct 2020
Pacific Gas and Electric Company's (PG&E) Emergency Operations Center, Meteorology team and Wildfire Safety Operations Center are working together and tracking a significant, offshore wind event starting Sunday that is forecast to have the driest...

23 oct 2020
The phenolic resin market is expected to grow by USD 4.56 billion during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the phenolic resin market in optimistic, probable, and pessimistic...

23 oct 2020
The global facial recognition market size is poised to grow by USD 3.35 billion during 2020-2024, progressing at a CAGR of almost 12% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date...



News published on 30 september 2020 at 17:43 and distributed by: